Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma.

Saved in:
Bibliographic Details
Title: Histamine H1 Receptor: A potential therapeutic target for pancreatic ductal adenocarcinoma.
Authors: Salmerón C; Department of Pharmacology, University of California, San Diego, La Jolla, California., Tomás Bort E; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom., Sriram K; Department of Pharmacology, University of California, San Diego, La Jolla, California., Javadi-Paydar M; Department of Pharmacology, University of California, San Diego, La Jolla, California., Smitham JE; Department of Pharmacology, University of California, San Diego, La Jolla, California., Pham K; Department of Pharmacology, University of California, San Diego, La Jolla, California., Grose RP; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., McCormick PJ; Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom., DiNardo A; Department of Dermatology, University of California San Diego, La Jolla, California., Weitz J; Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, California., Tiriac H; Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, California., Lowy AM; Department of Surgery, Division of Surgical Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, California., Insel PA; Department of Pharmacology, University of California, San Diego, La Jolla, California. Electronic address: pinsel@health.ucsd.edu.
Source: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2025 May; Vol. 392 (5), pp. 103573. Date of Electronic Publication: 2025 Apr 04.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1521-0103
DOI:10.1016/j.jpet.2025.103573